关注
Constantine Mitsiades
Constantine Mitsiades
Broad Institute Of MIT & Harvard, Dana-Farber Cancer Institute
在 broadinstitute.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ...
Cell 146 (6), 904-917, 2011
31162011
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ...
Science 343 (6168), 305-309, 2014
14842014
NF-κB as a therapeutic target in multiple myeloma
T Hideshima, D Chauhan, P Richardson, C Mitsiades, N Mitsiades, ...
Journal of Biological Chemistry 277 (19), 16639-16647, 2002
11812002
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
T Hideshima, C Mitsiades, G Tonon, PG Richardson, KC Anderson
Nature Reviews Cancer 7 (8), 585-598, 2007
11722007
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson, RL Schlossman, E Weller, T Hideshima, C Mitsiades, ...
Blood, The Journal of the American Society of Hematology 100 (9), 3063-3067, 2002
10532002
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ...
Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010
10452010
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, G Fanourakis, X Gu, ...
Proceedings of the National Academy of Sciences 99 (22), 14374-14379, 2002
9372002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades, CS Mitsiades, PG Richardson, V Poulaki, YT Tai, D Chauhan, ...
Blood, The Journal of the American Society of Hematology 101 (6), 2377-2380, 2003
9362003
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications.
N Mitsiades, CS Mitsiades, PG Richardson, V Poulaki, G Fanourakis, ...
Blood 100 (11), 105A-106A, 2002
9362002
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ...
Nature 511 (7511), 616-620, 2014
8432014
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ...
Cancer cell 8 (5), 407-419, 2005
8402005
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, PG Richardson, ...
Blood, The Journal of the American Society of Hematology 99 (12), 4525-4530, 2002
8332002
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ...
Cancer cell 5 (3), 221-230, 2004
7922004
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ...
Blood, The Journal of the American Society of Hematology 101 (4), 1530-1534, 2003
7522003
Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.
T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ...
Blood 100 (11), 814A-814A, 2002
7522002
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ...
Proceedings of the National Academy of Sciences 101 (2), 540-545, 2004
6762004
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
PG Richardson, E Blood, CS Mitsiades, S Jagannath, SR Zeldenrust, ...
Blood 108 (10), 3458-3464, 2006
6542006
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy
TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ...
Science 334 (6059), 1129-1133, 2011
6412011
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
R LeBlanc, LP Catley, T Hideshima, S Lentzsch, CS Mitsiades, ...
Cancer research 62 (17), 4996-5000, 2002
6332002
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
CS Mitsiades, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, ...
Oncogene 21 (37), 5673, 2002
6282002
系统目前无法执行此操作,请稍后再试。
文章 1–20